Literature DB >> 17547471

Antiepileptic drugs in the treatment of neuropathic pain.

Elon Eisenberg1, Yaron River, Ala Shifrin, Norberto Krivoy.   

Abstract

Antiepileptic drugs are an effective treatment for various forms of neuropathic pain of peripheral origin, although they rarely provide complete pain relief. Multiple multicentre randomised controlled trials have shown clear efficacy of gabapentin and pregabalin for postherpetic neuralgia and painful diabetic neuropathy. Theses drugs can be rapidly titrated and are well tolerated. Topiramate, lamotrigine, carbamazepine and oxcarbazepine are alternatives for the treatment of painful diabetic neuropathy, but should be titrated slowly. Carbamazepine remains the drug of choice for trigeminal neuralgia; however, oxcarbazepine and lamotrigine are potential alternatives. There is an apparent need for large-scale randomised controlled trials on the efficacy of antiepileptic drugs in neuropathic pain in general, and in cancer-related neuropathic pain and neuropathic pain of central origin in particular. Trials with long-term follow-up are required to establish the long-term efficacy of antiepileptic drugs in neuropathic pain. There is only limited scientific evidence to support the idea that drug combinations are likely to be more efficacious and safer than each drug alone; further studies are warranted in this area.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17547471     DOI: 10.2165/00003495-200767090-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  114 in total

Review 1.  Therapeutic safety monitoring: what to look for and when to look for it.

Authors:  C L Harden
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

2.  Pilot tolerability and effectiveness study of levetiracetam for postherpetic neuralgia.

Authors:  Michael C Rowbotham; Nira S Manville; Junlong Ren
Journal:  Neurology       Date:  2003-09-23       Impact factor: 9.910

3.  The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study.

Authors:  H Harke; P Gretenkort; H U Ladleif; S Rahman; O Harke
Journal:  Anesth Analg       Date:  2001-02       Impact factor: 5.108

4.  Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study.

Authors:  I Gilron; S L Booher; J S Rowan; M B Max
Journal:  Clin Neuropharmacol       Date:  2001 Mar-Apr       Impact factor: 1.592

5.  Lamotrigine in the treatment of painful diabetic neuropathy.

Authors: 
Journal:  Eur J Neurol       Date:  1998-03       Impact factor: 6.089

6.  Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy.

Authors:  F J Gómez-Pérez; R Choza; J M Ríos; A Reza; E Huerta; C A Aguilar; J A Rull
Journal:  Arch Med Res       Date:  1996       Impact factor: 2.235

7.  Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury.

Authors:  Funda Levendoglu; Cemile O Ogün; Onder Ozerbil; Tunç C Ogün; Hatice Ugurlu
Journal:  Spine (Phila Pa 1976)       Date:  2004-04-01       Impact factor: 3.468

8.  Carbamazepine inhibits spontaneous activity in experimental neuromas.

Authors:  K J Burchiel
Journal:  Exp Neurol       Date:  1988-11       Impact factor: 5.330

9.  Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices.

Authors:  David J Dooley; Cindy M Donovan; Wolfgang P Meder; Steven Z Whetzel
Journal:  Synapse       Date:  2002-09-01       Impact factor: 2.562

Review 10.  Comparative pharmacokinetics of the newer antiepileptic drugs.

Authors:  M Bialer
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

View more
  17 in total

1.  Neurologic bases for comorbidity of balance disorders, anxiety disorders and migraine: neurotherapeutic implications.

Authors:  Carey D Balaban; Rolf G Jacob; Joseph M Furman
Journal:  Expert Rev Neurother       Date:  2011-03       Impact factor: 4.618

Review 2.  Psychopharmacology in cancer.

Authors:  Seema M Thekdi; Antolin Trinidad; Andrew Roth
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

Review 3.  A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

Authors:  Howard N Bockbrader; David Wesche; Raymond Miller; Sunny Chapel; Nancy Janiczek; Paula Burger
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 4.  Pressure pain assessment may predict the outcome of spinal cord stimulation for refractory epilepsy.

Authors:  Li Feng; Li-Hua Fan; Duo-Zhi Wu
Journal:  Am J Clin Exp Immunol       Date:  2018-12-20

5.  Neuropathy of Trigeminal Nerve Branches After Oral and Maxillofacial Treatment.

Authors:  Jimoh Olubanwo Agbaje; Elke Van de Casteele; Marjolein Hiel; Ciska Verbaanderd; Ivo Lambrichts; Constantinus Politis
Journal:  J Maxillofac Oral Surg       Date:  2015-11-11

Review 6.  Metastatic bone pain: treatment options with an emphasis on bisphosphonates.

Authors:  Roger von Moos; Florian Strasser; Silke Gillessen; Kathrin Zaugg
Journal:  Support Care Cancer       Date:  2008-08-06       Impact factor: 3.603

Review 7.  Oxcarbazepine for neuropathic pain.

Authors:  Muke Zhou; Ning Chen; Li He; Mi Yang; Cairong Zhu; Fengbo Wu
Journal:  Cochrane Database Syst Rev       Date:  2017-12-02

Review 8.  An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy.

Authors:  Che S Zin; Lisa M Nissen; Maree T Smith; James P O'Callaghan; Brendan J Moore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Motor cortex stimulation for facial chronic neuropathic pain: A review of the literature.

Authors:  Guillermo A Monsalve
Journal:  Surg Neurol Int       Date:  2012-10-31

10.  Psychological interventions in the management of common skin conditions.

Authors:  Philip D Shenefelt
Journal:  Psychol Res Behav Manag       Date:  2010-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.